Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastenhuber, Edward R, Craig, John, Ramsey, Jon, Sullivan, Kevin M, Sage, Julien, de Oliveira, Sofia, Riehle, Kimberly J, Scott, John D, Gordan, John D, Bardeesy, Nabeel, Abou-Alfa, Ghassan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362920/
https://www.ncbi.nlm.nih.gov/pubmed/30951568
http://dx.doi.org/10.2147/JHC.S194764
_version_ 1783393021480402944
author Kastenhuber, Edward R
Craig, John
Ramsey, Jon
Sullivan, Kevin M
Sage, Julien
de Oliveira, Sofia
Riehle, Kimberly J
Scott, John D
Gordan, John D
Bardeesy, Nabeel
Abou-Alfa, Ghassan K
author_facet Kastenhuber, Edward R
Craig, John
Ramsey, Jon
Sullivan, Kevin M
Sage, Julien
de Oliveira, Sofia
Riehle, Kimberly J
Scott, John D
Gordan, John D
Bardeesy, Nabeel
Abou-Alfa, Ghassan K
author_sort Kastenhuber, Edward R
collection PubMed
description Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.
format Online
Article
Text
id pubmed-6362920
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63629202019-02-15 Road map for fibrolamellar carcinoma: progress and goals of a diversified approach Kastenhuber, Edward R Craig, John Ramsey, Jon Sullivan, Kevin M Sage, Julien de Oliveira, Sofia Riehle, Kimberly J Scott, John D Gordan, John D Bardeesy, Nabeel Abou-Alfa, Ghassan K J Hepatocell Carcinoma Meeting Report Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner. Dove Medical Press 2019-01-31 /pmc/articles/PMC6362920/ /pubmed/30951568 http://dx.doi.org/10.2147/JHC.S194764 Text en © 2019 Kastenhuber et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Meeting Report
Kastenhuber, Edward R
Craig, John
Ramsey, Jon
Sullivan, Kevin M
Sage, Julien
de Oliveira, Sofia
Riehle, Kimberly J
Scott, John D
Gordan, John D
Bardeesy, Nabeel
Abou-Alfa, Ghassan K
Road map for fibrolamellar carcinoma: progress and goals of a diversified approach
title Road map for fibrolamellar carcinoma: progress and goals of a diversified approach
title_full Road map for fibrolamellar carcinoma: progress and goals of a diversified approach
title_fullStr Road map for fibrolamellar carcinoma: progress and goals of a diversified approach
title_full_unstemmed Road map for fibrolamellar carcinoma: progress and goals of a diversified approach
title_short Road map for fibrolamellar carcinoma: progress and goals of a diversified approach
title_sort road map for fibrolamellar carcinoma: progress and goals of a diversified approach
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362920/
https://www.ncbi.nlm.nih.gov/pubmed/30951568
http://dx.doi.org/10.2147/JHC.S194764
work_keys_str_mv AT kastenhuberedwardr roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT craigjohn roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT ramseyjon roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT sullivankevinm roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT sagejulien roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT deoliveirasofia roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT riehlekimberlyj roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT scottjohnd roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT gordanjohnd roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT bardeesynabeel roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach
AT aboualfaghassank roadmapforfibrolamellarcarcinomaprogressandgoalsofadiversifiedapproach

Ejemplares similares